Chromocell reincorporates as Nevada corporation Channel Therapeutics; shares convert 1:1

Pelthos Therapeutics Inc.

On Nov 18, 2024, Chromocell Therapeutics (Delaware) merged into its Nevada subsidiary, Channel Therapeutics Corp, as the surviving entity.
Each outstanding share of Chromocell common stock converted into one share of Channel Therapeutics common stock (same symbol CHRO).
The reincorporation was approved by a majority of stockholders at the Oct 22, 2024 Annual Meeting; board and officers remain unchanged.
Stockholder rights may be affected by differences between Nevada Revised Statutes and Delaware General Corporation Law.

item 1.01 item 2.03 item 3.03 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Pelthos Therapeutics Inc.: Reincorporation and name change to Channel Therapeutics Corporation under Nevada charter (effective 2024-11-18).

Change: charter amendment
Effective: 2024-11-18

Exact text from the filing

As a result of the Reincorporation, as of the Effective Time, the Predecessor Registrant changed its name to “Channel Therapeutics Corporation” (the “ Name Change ”) pursuant to the Nevada Articles and Nevada Charter, filed with the with the Secretary of State of the State of Nevada on November 18, 2024 and November 5, 2024, respectively.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001753926-24-001955

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.